Once-a-month PrEP pill easily passes its first big test
Antibody-based PrEP did not stop most types of HIV – but is still hailed as a ‘game changer’
European PrEP programmes face two big issues: how to get more people coming forward, and how to serve them if they do
Molecular HIV surveillance: friend or foe?
Anthony Fauci: “I don’t do this because I’m a hero. I do it because it’s necessary.”
Meta-analysis finds no real difference in safety and effectiveness between tenofovir formulations
People with NNRTI resistance have poorer responses to dolutegravir, South African study finds
More weight gain in people starting HIV treatment with newer integrase inhibitors or darunavir
UK: Black people less likely to be engaged in HIV care, with more cases of viral rebound
